This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Breast Cancer Foundation, Inc. (NBCF), and Touch, The Black Breast Cancer Alliance (TOUCH).

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Gilead Sciences, Inc.

DATE OF LIVE ACTIVITY

Friday, April 22, 2022 from 12:00 – 1:00pm ET

TARGET AUDIENCE

The educational design of this activity addresses the needs of medical oncologists, pathologists, pharmacists, nurse practitioners, physician assistants, nurses, and other HCPs managing patients with TNBC.

STATEMENT OF NEED/PROGRAM OVERVIEW

Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer, disproportionally affecting young Black women. In addition, women from racial minorities tend to be diagnosed at a more advanced stage and experience higher rates of TNBC-related mortality. While standard chemotherapy has a high rate of failure in patients with TNBC, first-in-class targeted therapies offer hope of a more effective treatment for patients.

Join a distinguished panel of expert oncologists to explore how disparities in care negatively affect racial minority patients with TNBC, and the necessary steps healthcare professionals can take to address these inequities. Panelists will discuss how health care professionals can formulate plans to screen and diagnose these patients earlier and include genetic counselors on care teams to support patients after diagnosis. Experts will also review the evolving TNBC treatment landscape, the safety and efficacy of the newly approved anti-TROP-2, and additional agents under investigation.

Can your patients benefit from related education on the recognition and treatment of TNBC? Direct your patients to CancerCoachLive.com to access the patient-education activity, “Facing TNBC: Self-Advocacy and Decision-making.”

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Discuss solutions to address disparities in care for women of ethnic minorities diagnosed with TNBC
• Review recent advances in TNBC pathogenesis and prognosis
• Coordinate referrals to genetic testing and counseling
• Evaluate the mechanisms of action and safety and efficacy data for current and emerging TNBC agents
• Facilitate patient-centered care through accounts of real-world patient experiences

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter	Reported Financial Relationship
Tiffany A. Traina, MD Vice Chair, Oncology Care Section Head Triple Negative Breast Cancer Clinical Research Program Associate Attending Physician Breast Medicine Service Memorial Sloan Kettering Cancer Center Associate Professor Weill Cornell Medical College	Consulting Fee (e.g., Advisory Board): Agendia, AstraZeneca, Athenex, Ayala Pharmaceuticals, Blueprint Medicines, Daiichi Sankyo, Eisai, Ellipses Pharma, Exact Sciences, Foundation Medicine, Fuji Pharma, Genentech/Roche, Gilead Sciences, Ionis, Iteos Therapeutics, Merck, Pfizer, Puma Biotechnology, Seattle Genetics Contracted Research - Paid to Institution: AstraZeneca, Astellas Pharma, Ayala Pharmaceuticals, Carrick Pharm, Daiichi Sankyo, Eisai, Genentech/Roche, Innocrin Pharma, Immunomedics, Novartis, Pfizer
Lori L. Wilson, MD Associate Dean of Faculty Affairs, COM Division Chief, Surgical Oncology Chief of Breast Oncology Howard University Hospital and College of Medicine	Nothing to disclose

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager	Reported Financial Relationship
Rhys Williams, RN, MSN, FNP	Nothing to disclose
Lindsay Borvansky	Nothing to disclose
Andrea Funk	Nothing to disclose
Liddy Knight	Nothing to disclose
Ashley Cann	Nothing to disclose
Jaimee Harris-Gold	Nothing to disclose
Colleen Heffner	Nothing to disclose
Tariqa Ackbarali	Nothing to disclose
Juliet Copeland - Patient Participant	Nothing to disclose
Nicki Davis - Patient Participant	Nothing to disclose
Barbara Kaye - Patient Participant	Nothing to disclose
Yolanda Thomas - Patient Participant	Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.